Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

For a second year in a row, Currax delivered greater than 50% year-over-year revenue growth for CONTRAVE®/MYSIMBA® in 2024.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.